Retatrutide vs HGH 191AA

Retatrutide and HGH 191AA represent two divergent approaches in peptide research: one is a novel multi-agonist targeting metabolic pathways, while the other is a recombinant hormone identical to endogenous growth hormone. Retatrutide, developed by Eli Lilly, is a first-in-class triple agonist at GIP, GLP-1, and glucagon receptors, with Phase 2 and Phase 3 trials demonstrating substantial weight loss and glycemic benefits. In contrast, HGH 191AA (somatropin) is an FDA-approved recombinant human growth hormone used in deficiency states, with a well-characterized safety profile and decades of clinical use. This comparison highlights their mechanisms, evidence strength, and research applications, emphasizing that they are not interchangeable but may address complementary research questions in metabolism, body composition, and aging.

Retatrutide is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, designed to synergistically enhance energy expenditure and reduce caloric intake. In the Phase 2 trial (Jastreboff et al., NEJM 2023; n=338), the 12 mg dose led to a mean 24.2% body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Ongoing Phase 3 TRIUMPH trials are evaluating broader endpoints; TRIUMPH-4 (data reported Dec 2025) showed average weight loss up to 71.2 lbs and improvements in osteoarthritis-related pain. Expected FDA approval is projected for 2027–2028. Research suggests Retatrutide's glucagon receptor activity may uniquely promote energy expenditure beyond GLP-1 agonism alone, distinguishing it from earlier incretin-based therapies.

HGH 191AA refers to recombinant human growth hormone (somatropin), a 191-amino acid polypeptide identical in sequence to endogenous pituitary GH. It is FDA-approved for growth hormone deficiency in children and adults, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and HIV-associated wasting. The term '191AA' distinguishes it from the older 192-amino acid variant (somatrem), which had an extra methionine residue and higher immunogenicity. In research contexts, HGH 191AA is studied for its effects on body composition, including increased lean mass and reduced adiposity in GH-deficient adults, as well as potential anti-aging effects in healthy elderly populations. However, evidence for anti-aging benefits in non-deficient individuals remains limited and controversial, with studies showing modest improvements in body composition but no clear longevity benefit.

Retatrutide and HGH 191AA target distinct research domains with minimal overlap. Retatrutide is primarily investigated for weight management and metabolic health, including obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH), leveraging its triple agonist mechanism to modulate energy balance and glycemic control. HGH 191AA, by contrast, is studied for anti-aging and longevity, body composition (increasing lean mass, reducing fat mass), and recovery from catabolic states. While both may influence body weight, their mechanisms differ fundamentally: Retatrutide reduces appetite and increases energy expenditure via gut-brain signaling, whereas HGH 191AA promotes lipolysis and protein synthesis through IGF-1-mediated pathways. Researchers should select based on whether the study question involves metabolic regulation (Retatrutide) or growth hormone axis modulation (HGH 191AA).

Retatrutide: Gastrointestinal side effects are dose-dependent, occurring in 13–63% of participants across dose groups, including nausea, vomiting, diarrhea, and constipation. Most events are mild to moderate and partially mitigated by a lower starting dose (2 mg vs. 4 mg). Dose-dependent heart rate increases peak at 24 weeks and decline thereafter, a finding that warrants monitoring in cardiovascular studies. HGH 191AA: Common adverse effects include injection site reactions, fluid retention, joint pain, and carpal tunnel syndrome. Metabolic concerns include insulin resistance and hyperglycemia, which are dose-dependent and may precipitate diabetes in predisposed individuals. Endocrine effects such as gynecomastia and hypothyroidism (via unmasking of central hypothyroidism) have been reported. Long-term safety data for HGH 191AA are extensive due to FDA approval, whereas Retatrutide's safety profile continues to evolve in ongoing trials.